Literature DB >> 28923832

Rethinking End Points in Clinical Trials of Renoprotective Medication.

Aliza Thompson1.   

Abstract

Keywords:  Clinical Trials; Endpoint Determination; Renoprotective Medication

Mesh：

Year:  2017        PMID： 28923832      PMCID： PMC5628724          DOI： 10.2215/CJN.09040817

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  3 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

Authors:  Misghina Weldegiorgis; Dick de Zeeuw; Jamie P Dwyer; Peter Mol; Hiddo J L Heerspink
Journal:  Clin J Am Soc Nephrol       Date:  2017-09-18       Impact factor: 8.237

3.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.